Blood Journal · 13 Nov 2026
Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS
Andrew M. Brunner, Ted M. Getz, Kelly Pugh, Jan Philipp Bewersdorf, Tariq Kewan, Uma Borate, Amy E DeZern, Uwe Platzbecker, Mikkael A Sekeres, Andrew H Wei, Rena J. Buckstein, Gail J. Roboz, Michael R Savona, Sanam Loghavi, Robert P Hasserjian, Pierre Fenaux, David A Sallman, Christopher S Hourigan, Matteo Giovanni Della Porta, Stephen D Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal M. Patnaik, Maria E Figueroa, Hetty E Carraway, Omar Abdel-Wahab, Daniel T Starczynowski, Eric Padron, Jacqueline Boultwood, Steven D Gore, Naval G Daver, Jane E. Churpek, John M Bennett, Alan F. List, Shahram Kordasti, Adrian Mosquera Orgueira, Klaus H Metzeler, Francesc Sole, Lisa Pleyer, Arjan A. van de Loosdrecht, Thomas Cluzeau, David Peter Steensma, Ghulam J Mufti, Lionel Adès, Marie Sebert, Anne Sophie Platzbecker, Yazan F. Madanat, R. Coleman Lindsley, Katharina S Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer M. Zeidan
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.